MedPath

Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes

Completed
Conditions
Pediatric Multiple Sclerosis
Registration Number
NCT03066752
Lead Sponsor
The Hospital for Sick Children
Brief Summary

Up to 65% of patients with multiple sclerosis (MS) experience cognitive dysfunction. Diminution of mental capacity has a pervasive and profound impact on their quality of life. Subtle changes in white matter predict cognitive changes in these patients but how this disrupts brain function remains unclear. Development of effective therapeutics to restore normal cognition hinges on elucidating these functional changes. The investigators seek to uncover the patho-physiological basis for cognitive decline in MS. The investigators hypothesize that cognitive decline originates from disrupted gamma oscillations and that gamma oscillations are disrupted by molecular changes triggered by demyelination.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Neurocognitive Testing90 minutes

Penn Computerized Neurocognitive Battery

Neurological Exam - Standard physical exam performed by the neurologist to determine the Expanded Disability Status Scale (EDSS) score.20 minutes
Neuronal responses during simple and choice reaction time tasks60 minutes

Video-based eye tracking in the MEG

MRI scans of the brain, including Diffusion Tensor Imagine (DTI)90 minutes
Clinical Interview10 minutes

Series of questions about the participant's demographic and clinical information including, current and past health, family history, and medications.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hospital for Sick Children

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath